Business Overview: 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT)

---

Executive Summary

4D Molecular Therapeutics, Inc. is a Delaware corporation headquartered in Emeryville, California, describing itself as "a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics." The company develops AAV-based genetic medicines for serious retinal and pulmonary diseases, built on its proprietary Therapeutic Vector Evolution (TVE) capsid-discovery platform.

4D Molecular Therapeutics is a clinical-stage, pre-revenue biotech company with a non-affiliate market value of approximately $166.5 million (as of June 30, 2025), advancing its lead program 4D-150 through two pivotal Phase 3 trials in wet AMD and a planned Phase 3 in diabetic macular edema, backed by an $85.0 million upfront payment and up to $335.5 million in milestones from a partnership with Otsuka Pharmaceutical.

---

1. Core Business Model & How They Work

4D Molecular Therapeutics discovers and develops one-time, durable genetic medicines intended to replace chronic, repeat-injection standards of care in retinal and lung disease, monetized through eventual product sales and near-term partnership milestone/royalty payments.

[ TVE Platform (~1B Synthetic AAV Capsids) ] ➡️ [ Capsid Selection (R100 Retina / A101 Lung) ] ➡️ [ Clinical Pipeline (4D-150, 4D-175, 4D-710, 4D-725) ] ➡️ [ Partnership Milestones (Otsuka, CFF) + Future Product Sales ]

Key Operational Drivers

1. Therapeutic Vector Evolution (TVE) Platform: A directed-evolution approach using non-human primates to select AAV capsids from a library of roughly one billion synthetic sequences, yielding proprietary vectors R100 (retina) and A101 (lung) that underpin the entire pipeline.
2. Lead Program Momentum (4D-150): The company's lead one-time intravitreal gene therapy for wet AMD and diabetic macular edema (DME) is already in two pivotal Phase 3 trials (4FRONT-1 and 4FRONT-2) for wet AMD, with a global Phase 3 DME trial expected to start Q3 2026.
3. Otsuka Pharmaceutical Partnership: Otsuka holds exclusive rights to 4D-150 in Japan, China, Australia, and other APAC markets, having paid an $85.0 million upfront payment with up to $335.5 million in additional milestones plus royalties — both a validation signal and a non-dilutive funding source.
4. Cystic Fibrosis Foundation Partnership: CFF funds development of 4D-710 for cystic fibrosis and purchased 776,398 shares for $7.5 million in October 2025, with up to $3.6 million more tied to clinical milestones.
5. Pipeline Depth Beyond the Lead Asset: 4D-175 (geographic atrophy, open IND) and 4D-725 (alpha-1 antitrypsin deficiency, CIRM-funded, preclinical) extend the platform beyond the lead retina and lung programs.

---

2. Product Portfolio

---

3. Competitive Landscape

4D Molecular Therapeutics faces indication-specific competitors:

• Wet AMD/DME: AbbVie/REGENXBIO (ABBV-RGX-314), Adverum/Eli Lilly (Ixo-Vec), EyePoint, Ocular Therapeutix, Kodiak, Merck, Regeneron (EYLEA), and Roche.
• Geographic Atrophy: Apellis (SYFOVRE) and Astellas (IZERVAY), among others.
• Cystic Fibrosis: Vertex (the dominant CFTR-modulator incumbent), plus Sionna, Krystal, Arcturus, and Recode.

4D's core competitive thesis is durability: a one-time gene therapy intended to replace today's standard of repeat intravitreal injections (e.g., Regeneron's EYLEA) or chronic modulator therapy (Vertex), rather than competing directly on near-term price.

---

4. Strategic Strengths & Risks

Strengths (The Moat)

• Proprietary, hard-to-replicate discovery platform: The TVE platform's roughly one-billion-sequence capsid library and directed-evolution approach in non-human primates represent a differentiated, IP-protected discovery engine underlying the entire pipeline.
• Big-pharma validation and non-dilutive funding: Otsuka's $85.0 million upfront payment and the Cystic Fibrosis Foundation's direct equity investment both validate the platform and extend the company's cash runway without full dilution.
• Late-stage lead asset: 4D-150 is already in dual pivotal Phase 3 trials for wet AMD, placing the company's most advanced program meaningfully closer to potential approval than most gene-therapy peers.
• Multi-indication pipeline depth: Four distinct clinical/preclinical programs across two disease areas (retina and lung) reduce single-asset binary risk relative to a one-product biotech.

Risks

• Pre-commercial, loss-making stage: The company has recurring net losses and expects continued significant losses until (if ever) a product reaches commercial approval.
• Clinical and regulatory binary risk: Phase 3 trial outcomes and FDA approval decisions for 4D-150 are binary events that could significantly affect the company's value regardless of platform quality.
• Crowded competitive field with entrenched incumbents: Regeneron's EYLEA and Vertex's CFTR modulators are dominant, well-established standards of care that 4D-150 and 4D-710 must displace or meaningfully improve upon.
• Dependence on partnerships for ex-U.S. value and some funding: Reliance on Otsuka and CFF for international rights and non-dilutive capital means the company's economics in key areas are partly outside its own control.

---

5. Financial Overview

---

6. Summary Conclusion

4D Molecular Therapeutics has built a differentiated AAV-capsid discovery platform that has already produced a late-stage lead asset (4D-150) in pivotal Phase 3 trials for wet AMD, validated by a substantial upfront payment and milestone package from Otsuka Pharmaceutical, alongside a pipeline extending into diabetic macular edema, geographic atrophy, and cystic fibrosis.

The company's central forward risk is binary clinical and regulatory execution: as a pre-revenue, loss-making biotech, 4D Molecular Therapeutics' value depends almost entirely on 4D-150's Phase 3 trial results and eventual approval against entrenched standards of care like Regeneron's EYLEA, with the broader multi-asset pipeline offering some diversification but not eliminating that core binary risk.